Expression of programmed death-ligand 1 in hepatocellular carcinoma and its clinical significance
10.3969/j.issn.1001-5256.2016.08.047
- VernacularTitle:程序性死亡因子配体1在肝细胞癌中的表达及意义
- Author:
Liu YANG
1
;
Xiling ZHU
;
Gong LI
Author Information
1. Second Department of Oncology, Clinical College of General Hospital of Armed Police Forces, Anhui Medical University, Beijing 100039, China
- Publication Type:Research Article
- Keywords:
carcinoma, hepatocellular;
programmed death ligand 1;
immunotherapy;
review
- From:
Journal of Clinical Hepatology
2016;32(8):1630-1634
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the immunotherapy based on the blocking of programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway has achieved encouraging progress in the treatment of malignant tumors such as melanoma and lung cancer. More and more studies have focused on its role in hepatocellular carcinoma (HCC). This article introduces the mechanism of action of PD-1/PD-L1, expression of PD-L1 in HCC tissues, and its basic and clinical research in the treatment of HCC, and points out that PD-L1 plays an important role in tumor immune escape and is expected to become an independent index for evaluating the prognosis of HCC. The discovery of PD-1/PD-L1 pathway provides a new target for immunotherapy for HCC.
